We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
- Authors
Barnabei, Agnese; Strigari, Lidia; Marchetti, Paolo; Sini, Valentina; De Vecchis, Liana; Corsello, Salvatore Maria; Torino, Francesco
- Abstract
Background. The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Mullerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients. Materials and Methods. To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms "amenorrhea/chemically induced," "ovarian reserve," "anti-Mullerian hormone/blood," and "breast neoplasms/drug therapy." Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline AMH and age model. Results. The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602-0.904) compared with those older than 40 years (0.678; 95% CI: 0.491-0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy. Conclusion. After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal women requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures.
- Subjects
AGE distribution; BREAST tumors; CONFIDENCE intervals; FERTILITY; SEX hormones; MEDLINE; META-analysis; ONLINE information services; OVARIES; T-test (Statistics); SYSTEMATIC reviews; LOGISTIC regression analysis; CONTINUING education units; RECEIVER operating characteristic curves; DATA analysis software; STATISTICAL models; DESCRIPTIVE statistics; ODDS ratio; DISEASE complications
- Publication
Oncologist, 2015, Vol 20, Issue 10, p1111
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2015-0183